CCL11 (eotaxin-1): A new diagnostic serum marker for prostate cancer

Prostate

Volumn 73, Issue 6, 2013, Pages 573-581

  Agarwal, Manisha ^a   He, Chang ^a   Siddiqui, Javed ^b   Wei, John T ^a,b   Macoska, Jill A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

biomarker; cancer; CCL11; Eotaxin 1; prostate; serum

Indexed keywords

CCL1 CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

AGED; BIOLOGICAL MARKERS; BIOPSY; CHEMOKINE CCL1; CHEMOKINE CCL11; DIAGNOSIS, DIFFERENTIAL; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875814654     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22597     Document Type: Article

References (50)

1. Luciani LG, De Giorgi G, Valotto C, Zanin M, Bierti S, Zattoni F,. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings. Urology 2006; 67 (3): 555-558.
2. Inahara M, Suzuki H, Kojima S, Komiya A, Fukasawa S, Imamoto T, Naya Y, Ichikawa T,. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology 2006; 68 (4): 815-819.
3. Kravchick S, Peled R, Dorfman D, Agulansky L, Ben-Dor D, Cytron S,. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL. Urology 2005; 66 (3): 542-546.
4. Pelzer AE, Tewari A, Bektic J, Berger AP, Frauscher F, Bartsch G, et al. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: Observation and clinical implications from Tyrol screening project. Urology 2005; 66 (5): 1029-1033.
5. Gilbert SM, Cavallo CB, Kahane H, Lowe FC,. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology 2005; 65 (3): 549-553.
6. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360 (13): 1320-1328.
7. Al-Azab R, Toi A, Lockwood G, Kulkarni GS, Fleshner N,. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology 2007; 69 (1): 103-107.
8. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J,. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53 (3): 581-589.
9. Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan DW, et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: Results from the Baltimore longitudinal study of aging. J Urol 2002; 167 (6): 2484-2487; discussion 7-8.
10. Berger AP, Cheli C, Levine R, Klocker H, Bartsch G, Horninger W,. Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL. Urology 2003; 62 (5): 840-844.
11. Berger AP, Deibl M, Strasak A, Bektic J, Pelzer AE, Klocker H, et al. Large-scale study of clinical impact of PSA velocity: Long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology 2007; 69 (1): 134-138.
12. Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL, et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 2006; 68 (2): 352-356.
13. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: An ecological study. Lancet Oncol 2008; 9 (5): 445-452; PMCID: 2760747.
14. Miller DC, Hollenbeck BK,. Missing the mark on prostate-specific antigen screening. JAMA 2011; 306 (24): 2719-2720.
15. Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA,. Molecular pathology of prostate cancer. Cancer Biomark 2010; 9 (1-6): 441-459.
16. Martin NE, Mucci LA, Loda M, Depinho RA,. Prognostic determinants in prostate cancer. Cancer J 2011; 17 (6): 429-437; PMCID: 3240856.
17. Netto GJ, Cheng L,. Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med 2012; 136 (4): 372-390.
18. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG,. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol Available online 19 May 2011, ISSN 1078-1439; PMCID: 3210917.
19. Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA,. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 2005; 4 (6): 291-298.
20. Begley LA, Kasina S, MacDonald J, Macoska JA,. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008; 43 (2): 194-199; PMCID: 2538565.
21. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, et al. CXCL5 promotes prostate cancer progression. Neoplasia 2008; 10 (3): 244-254; PMCID: 2262133.
22. Begley LA, MacDonald JW, Day ML, Macoska JA,. CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem 2007; 282 (37): 26767-26774.
23. Kasina S, Macoska JA,. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol 2012; 351 (2): 249-263; PMCID: 3307100.
24. Kasina S, Scherle PA, Hall CL, Macoska JA,. ADAM-mediated amphiregulin shedding and EGFR transactivation. Cell Prolif 2009; 42 (6): 799-812; PMCID: 3167473.
25. Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV,. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate 2008; 68 (4): 442-452.
26. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: Results from the prostate cancer prevention trial. J Natl Cancer Inst 2006; 98 (8): 529-534.
27. Siu W, Dunn RL, Shah RB, Wei JT,. Use of extended pattern technique for initial prostate biopsy. J Urol 2005; 174 (2): 505-509.
28. Heveker N, Montes M, Germeroth L, Amara A, Trautmann A, Alizon M, et al. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. Curr Biol 1998; 8 (7): 369-376.
29. Kowalska MA, Ratajczak J, Hoxie J, Brass LF, Gewirtz A, Poncz M, et al. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: Determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol 1999; 104 (2): 220-229.
30. Wang JF, Liu ZY, Groopman JE,. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood 1998; 92 (3): 756-764.
31. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD,. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 2000; 86 (2): 131-138.
32. Roos RS, Loetscher M, Legler DF, Clark-Lewis I, Baggiolini M, Moser B,. Identification of CCR8, the receptor for the human CC chemokine I-309. J Biol Chem 1997; 272 (28): 17251-17254.
33. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, et al. Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007; 51 (2): 524-533.
34. Miller MD, Krangel MS,. The human cytokine I-309 is a monocyte chemoattractant. Proc Natl Acad Sci USA 1992; 89 (7): 2950-2954; PMCID: 48781.
35. Zingoni A, Soto H, Hedrick JA, Stoppacciaro A, Storlazzi CT, Sinigaglia F, et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 1998; 161 (2): 547-551.
36. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66 (1): 96-107.
37. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003; 83 (8): 1131-1146.
38. Kramer G, Mitteregger D, Marberger M,. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51 (5): 1202-1216.
39. McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA,. Leukocytic promotion of prostate cellular proliferation. Prostate 2010; 70 (4): 377-389; PMCID: 3167472.
40. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD,. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996; 2 (4): 449-456.
41. Gerber BO, Zanni MP, Uguccioni M, Loetscher M, Mackay CR, Pichler WJ, et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol 1997; 7 (11): 836-843.
42. Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, et al. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 1997; 100 (5): 1137-1143; PMCID: 508288.
43. Sallusto F, Mackay CR, Lanzavecchia A,. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997; 277 (5334): 2005-2007.
44. Quick ML, Mukherjee S, Rudick CN, Done JD, Schaeffer AJ, Thumbikat P,. CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis. Am J Physiol Regul Integr Comp Physiol 2012; 303 (6): R580-R589.
45. Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE,. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 2000; 44 (1): 19-25.
46. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, et al. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 2010; 9 (6): 1755-1763; PMCID: 2913168.
47. Johrer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, Ramoner R, et al. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res 2005; 11 (7): 2459-2465.
48. Sosnoski DM, Krishnan V, Kraemer WJ, Dunn-Lewis C, Mastro AM,. Changes in cytokines of the bone microenvironment during breast cancer metastasis. Int J Breast Cancer 2012; 2012: Article ID 160265, 9 pages, PMCID: 3270522.
49. Egler RA, Li Y, Dang TA, Peters TL, Leung E, Huang S, et al. An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring. Proteomic Clin Appl 2011; 5 (9-10): 532-541.
50. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3 (94): 94ra72; PMCID: 3245713.